scholarly journals Intravesical Botulinum Toxin A Injections for Bladder Pain Syndrome/Interstitial Cystitis: A Systematic Review and Meta-Analysis of Controlled Studies

2016 ◽  
Vol 22 ◽  
pp. 3257-3267 ◽  
Author(s):  
Junpeng Wang ◽  
Qiang Wang ◽  
Qinghui Wu ◽  
Yang Chen ◽  
Peng Wu
Keyword(s):  
Systematic Review ◽  
Botulinum Toxin ◽  
Interstitial Cystitis ◽  
Botulinum Toxin A ◽  
Meta Analysis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Toxin A ◽  
Bladder Pain

scholarly journals Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis

Toxins ◽  
2016 ◽  
Vol 8 (7) ◽  
pp. 201 ◽  
Author(s):  
Bin Chiu ◽  
Huai-Ching Tai ◽  
Shiu-Dong Chung ◽  
Lori Birder
Keyword(s):  
Botulinum Toxin ◽  
Interstitial Cystitis ◽  
Botulinum Toxin A ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Toxin A ◽  
Bladder Pain

Trigonal Injection of Botulinum Toxin A in Patients with Refractory Bladder Pain Syndrome/Interstitial Cystitis

2010 ◽  
Vol 58 (3) ◽  
pp. 360-365 ◽  
Author(s):  
Rui Pinto ◽  
Tiago Lopes ◽  
Bárbara Frias ◽  
André Silva ◽  
João Alturas Silva ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Interstitial Cystitis ◽  
Botulinum Toxin A ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Toxin A ◽  
Bladder Pain

scholarly journals Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome—Possible Pathomechanisms and Practical Issues

Toxins ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 641 ◽  
Author(s):  
Jia-Fong Jhang
Keyword(s):  
Botulinum Toxin ◽  
Interstitial Cystitis ◽  
Standard Treatment ◽  
Botulinum Toxin A ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Placebo Control ◽  
Toxin A ◽  
Bladder Pain ◽  
Number Of Patients

Treatment for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) is always challenging for urologists. The main mechanism of the botulinum toxin A (BoNT-A) is inhibition of muscle contraction, but the indirect sensory modulation and anti-inflammatory effect in the bladder also play important roles in treating patients with IC/BPS. Although current guidelines consider BoNT-A injection to be a standard treatment, some practical issues remain debatable. Most clinical evidence of this treatment comes from retrospective uncontrolled studies, and only two randomized placebo-control studies with limited patient numbers have been published. Although 100 U BoNT-A is effective for most patients with IC/BPS, the potential efficacy of 200 U BoNT-A has not been evaluated. Both trigone and diffuse body BoNT-A injections are effective and safe for IC/BPS, although comparison studies are lacking. For IC/BPS patients with Hunner’s lesion, the efficacy of BoNT-A injection remains controversial. Most patients with IC/BPS experience symptomatic relapse at six to nine months after a BoNT-A injection, although repeated injections exhibit a persistent therapeutic effect in long-term follow-up. Further randomized placebo-controlled studies with a larger number of patients are needed to support BoNT-A as standard treatment for patients with IC/BPS.

Sign in / Sign up

Export Citation Format

Share Document